Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer By Ogkologos - April 21, 2026 66 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROSELLA study Source RELATED ARTICLESMORE FROM AUTHOR ESMO Strengthens Global Oncology Collaboration Through its Growing Presence in the Asia-Pacific Pemigatinib Prolongs mPFS Over Chemotherapy in Patients with Advanced Cholangiocarcinoma with FGFR2 Fusions or Rearrangements FDA Approves Atezolizumab for Adjuvant Treatment of Muscle Invasive Bladder Cancer in Patients with Molecular Residual Disease MOST POPULAR Bean there done that: Can swapping to pulses be the new... February 11, 2022 5 Tips to Move Beyond the Bedside May 17, 2021 ctDNA Monitoring Improves Early Relapse Detection After Treatment with Axicabtagene Ciloleucel... June 22, 2021 Are differences in treatment driving variation in ovarian cancer survival internationally? August 11, 2020 Load more HOT NEWS Woman Discovers Breast Lump in the Shower After Dropping Her Loofah,... Woman With Double Mastectomy Invents Breastfeeding Simulator For Breast Cancer Survivors EMA Recommends Granting a Marketing Authorisation for Biosimilar Pegfilgrastim “Chameleon-Like” Breast Cancer Cells Disguised as Neurons Can Lead to Brain...
